Pharmacokinetics and Pharmacodynamics of [68Ga]Ga-R54, a CXCR4-Targeted Radiopharmaceutical, in Patients with Advanced CXCR4-Positive Solid Tumors

The primary objective of this study is to evaluate the **pharmacokinetics** and **pharmacodynamics** of the radiopharmaceutical [68Ga]Ga-R54, a CXCR4-targeted tracer, in patients with advanced solid tumors. These tumors include breast, lung, colon, ovary, and pancreas neoplasms characterized by positive CXCR4 expression as determined by immunohistochemistry. Understanding the pharmacokinetics and pharmacodynamics of this tracer is clinically relevant as it may provide insights into the tracer's distribution, metabolism, and potential therapeutic implications in targeting CXCR4-expressing tumors.

The clinical trial involves participants diagnosed with **advanced solid neoplasm**, specifically in the breast, lung, colon, ovary, and pancreas, characterized by positive CXCR4 expression as determined by immunohistochemistry. The study population includes both male and female subjects, with an age range encompassing adults and older adults. The trial does not focus on a vulnerable population. The sponsor has not provided information regarding the total number of participants. Selection criteria for the trial population, as well as any lifestyle considerations such as diet or physical activity, have not been disclosed. Key inclusion or exclusion criteria are not specified in the available data.

The clinical trial is designed to evaluate the **pharmacokinetics** and **pharmacodynamics** of the radiopharmaceutical [68Ga]Ga-R54, a CXCR4-targeted tracer, in patients with advanced solid tumors. This study is a Phase 1 trial, which will be conducted in a randomized, double-blind, and controlled manner. The trial is expected to commence recruitment on August 1, 2024, and is anticipated to conclude by August 1, 2025. The target population includes patients with advanced solid neoplasms, such as breast, lung, colon, ovary, and pancreas cancers, characterized by positive CXCR4 expression as determined by immunohistochemistry.

Participants will undergo a series of study visits, beginning with an inclusion visit, which serves as the screening phase to assess eligibility based on predefined criteria. Following successful screening, participants will be enrolled in the trial and will attend scheduled follow-up visits to monitor the effects of the investigational product and collect necessary data. The end-of-study visit will mark the completion of the trial for each participant, where final assessments will be conducted to evaluate the overall outcomes and safety of the intervention.

The expected duration of participant involvement in the trial is approximately one year, aligning with the overall trial timeline. Conditions that may lead to early termination from the study include adverse reactions to the investigational product, withdrawal of consent, or any significant protocol deviations. The trial aims to gather comprehensive data to inform future research and potential therapeutic applications of the CXCR4-targeted radiopharmaceutical in oncology.

The clinical trial involves the administration of an **experimental medication**. However, specific details regarding the name, pharmaceutical form, dosage, route, and frequency of administration of the experimental medication are not provided in the available data. The trial documentation does not specify whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. Additionally, there is no information on the maximum daily dose, total dose, or treatment period for the experimental medication.

In addition to the experimental medication, the trial may include the use of **non-experimental treatments** such as standard-of-care therapy, placebo, or comparator treatments. However, the data does not provide explicit details about these treatments. Information regarding the administration, dosing schedules, and participant compliance monitoring for these non-experimental treatments is also not available in the provided data.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 1 study, indicating an early stage of clinical research primarily focused on safety and dosage. The trial is scheduled to commence recruitment on August 1, 2024, with an estimated completion date of August 1, 2025. Although specific efficacy endpoints are not detailed, typical Phase 1 trials often involve preliminary assessments of efficacy alongside safety evaluations. These assessments may include the use of validated scales, laboratory tests, or other objective measures to gather data on the investigational product's impact on the targeted medical condition. The data collection and analysis will be conducted in accordance with standard clinical trial protocols, ensuring rigorous and systematic evaluation of the investigational product's potential therapeutic benefits.